Biosino Bio-Technology & Science Inc.
8247.HK
Hong Kong Stock Exchange2.88
HKD
+0.02
- -
ISIN
CNE100000288
Return %
Stock
S&P500
1Y
396.55
24.99
3Y
188.00
70.19
5Y
118.18
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chen Peng
- Full Time Employees
- 450
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- No. 27, Chaoqian Road Beijing BJ People's Republic of China 102200
- IPO Date
- Feb 27, 2006
- Website
- sinobio.com.cn
- Similar Companies
- Business
- Biosino Bio-Technology & Science Inc. operates as a China-based provider of in vitro diagnostic (IVD) reagents and related medical instrumentation, focusing on the research, development, manufacture, sale, and distribution of immunology, clinical chemistry, molecular, hematology, and related diagnostic products. It targets hospital laboratories, clinical centers, and diagnostic service providers with a broad portfolio of reagents, assay kits, and analytical instruments designed for liver function, lipid profiling, renal function, cardiovascular markers, metabolic and special protein panels, trace elements, and sugar metabolism, supported by a nationwide sales and technical service network. Main products and services IVD reagents and assay kits for clinical chemistry, immunology, molecular diagnostics, hematology, and specialty panels; diagnostic instruments and analyzers; raw materials and analytical components; related software and data management solutions; technical service, installation, validation, and maintenance; training and customer support; international trade and distribution services; instrument integrator solutions and turnkey diagnostic workflows. Latest major company changes Biosino announces ongoing expansion of its domestic marketing network and overseas branches, reinforcing a dual domestic and international growth strategy; it completes partnerships and representative arrangements with hundreds of agents and dealers across China to strengthen regional coverage; it pursues continued product innovation, including new diagnostic reagents and accompanying analytical instruments; the company reports potential acquisitions and strategic alliances to broaden its IVD portfolio and geographic reach; it reinforces lean management and scientific capacity to accelerate new product launches and market adoption in the past 1–2 years. Additional context The company operates primarily in the IVD sector with a diversified product mix spanning clinical chemistry, immunology, molecular diagnostics, hematology, and related instruments; it serves domestic Chinese markets with expansion into overseas channels; its corporate structure includes a broad network of distributors and service centers; it is headquartered in Beijing, with multiple subsidiaries and regional offices to support manufacturing, distribution, and after-sales service. The business model emphasizes innovation, manufacturing efficiency, and a nationwide and international go-to-market approach to deliver comprehensive diagnostic solutions.